AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25099545
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline infusion, 0 kcal)
Trial: 22267334
Drug: Conventional immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppressive (IS) treatment
Trial: 18520801
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 80 mg/m on day 1 and Vinorelbine (VNR) 20 mg/m on days 1 and 8 every 4 weeks with concurrent thoracic radiotherapy (TRT) of 60 Gy in 30 fractions.
Trial: 12028321
Drug: Frovatriptan (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan (oral administration)
Trial: 10496576
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Trial: 10496576
Drug: 5-day hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Trial: 10496576
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (21% oxygen for 1 hour per day at 1.2 atm)
Trial: 2453895
Drug: Buprenorphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.3 mg)
Trial: 31985248
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy (manualized intervention)
Trial: 19398279
Drug: Preparing for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparing for the Drug Free Years (PDFY)
Trial: 16317266
Drug: Erlotinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (50 mg/d) with chemoradiation.
Trial: 2702966
Drug: Adenosine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (maximum tolerated dose: 10.3 +/- 2.3 mg)
Trial: 31289092
Drug: 4 L split‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Trial: 31289092
Drug: 6 L split‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Trial: 31289092
Drug: 6 L split‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 L split‐dose PEG‐ELS
Trial: 31289092
Drug: 4 L split‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L split‐dose PEG‐ELS
Trial: 12946073
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side (no AMSA injection)
Trial: 3027604
Drug: Yohimbine (effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (effective dose)
Trial: 28028194
Drug: Allopurinol (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300-600 mg/d)
Trial: 27909139
Drug: SBI-087 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBI-087 (200 mg)
Trial: 24828019
Drug: Folate-5: 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate-5: 5 mg/day folate supplements
Trial: 24828019
Drug: Folate-1: 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate-1: 1 mg/day folate supplements
Trial: 21751197
Drug: 15 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/m² clofarabine daily × 5 days
Trial: 8881132
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of nadroparin calcium (7500 anti-Xa IC units)
Trial: 21890277
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (300 mg)
Trial: 1576050
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (600 mg)
Trial: 1576050
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (1200 mg)
Trial: 28127561
Drug: Traditional immunosuppressants
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional immunosuppressants
Trial: 23023231
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose plain radiography
Trial: 18312042
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (18 mg to 54 mg)
Trial: 12421104
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg/day
Trial: 9333057
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin 500 mg
Trial: 8471403
Drug: Fengabine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fengabine 400 mg
Trial: 3836854
Drug: 40 749
RxNorm normalized name: petrolatum 0.749 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 749 RP (2 mg/kg)
Trial: 29220295
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m2 given once a week
Trial: 29220295
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 given once every 3 weeks
Trial: 19477881
Drug: Nicotine (Nicorette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (Nicorette 2 mg)
Trial: 18705297
Drug: Mesalazine 800mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 800mg/daily (group M1)
Trial: 11151579
Drug: 2‐stage endosseous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐stage endosseous root‐form implants (3 different implant systems)
Trial: 6363395
Drug: Rapid intramuscular
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intramuscular neuroleptization at 2 mg per dose
Trial: 29898587
Drug: BoNT‐A monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A monotherapy (N=18)
Trial: 15246905
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral nitrates
Trial: 15246905
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily oral nitrates
Trial: 24602137
Drug: HM30181 (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181 (15, 60, or 180 mg)
Trial: 9197805
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for STD (Comparison Group)
Trial: 31686094
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (LipiDiDiet product)
Trial: 25951165
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g in 1000 mL of 0.9% saline solution infused over 24 hours for each of the 3 preoperative days)
Trial: 25951165
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mL of 0.9% saline solution for the same time period)
Trial: 22770431
Drug: Conventional bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional bleaching technique with 38% hydrogen peroxide gel for one hour
Trial: 22770431
Drug: Sealed bleaching
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealed bleaching technique with 38% hydrogen peroxide gel for one hour
Trial: 16820257
Drug: Reboxetine 4
RxNorm normalized name: reboxetine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 4 mg/day bid + Sertraline 50 mg/day od
Trial: 10678926
Drug: Lower-dose vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose vaccine (5 x 10(7) CFU)
Trial: 10678926
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and lower-dose vaccines
Trial: 8290185
Drug: 30-minute incremental
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute incremental oxytocin infusion regimen
Trial: 8290185
Drug: 15-minute incremental
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-minute incremental oxytocin infusion regimen
Trial: 2566779
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 4 months
Trial: 27677865
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of prednisone
Trial: 1097222
Drug: Maintenance administration
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance administration of prednisone
Trial: 1097222
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prednisone when headaches began
Trial: 17876505
Drug: Methylphenidate combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate combined with multimodal behavior therapy
Trial: 16426470
Drug: Meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.5 mg kg(‐1)
Trial: 14557583
Drug: L-DOPA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (400 mg/day)
Trial: 10848743
Drug: Amorolfine 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine 5% solution nail lacquer + oral terbinafine for 6 weeks (AT6 group)
Trial: 10848743
Drug: Amorolfine 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine 5% solution nail lacquer + oral terbinafine for 12 weeks (AT12 group)
Trial: 7907662
Drug: Intravenous L-2-oxothiazolidine-4-carboxylic
RxNorm normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 3, 10, or 30 mg/kg
Trial: 7907662
Drug: Intravenous L-2-oxothiazolidine-4-carboxylic
RxNorm normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 100 mg/kg
Trial: 7907662
Drug: Intravenous L-2-oxothiazolidine-4-carboxylic
RxNorm normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine)
Trial: 2640452
Drug: Furosemide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (0.5 mg/kg body weight)
Trial: 18155050
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 5 mg per mL
Trial: 18155050
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 10 mg per mL
Trial: 17184102
Drug: Esterified conjugated
RxNorm normalized name: estrogens, conjugated (USP) / estrogens, esterified (USP) / medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified conjugated estrogens (ECE) 0.312 mg/day (low‐dose) (n = 17)
Trial: 9093637
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg DEC
Trial: 9093637
Drug: DEC (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (various doses)
Trial: 2866071
Drug: Rectal biopsies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal biopsies
Trial: 27321474
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral progesterone daily
Trial: 12014812
Drug: Therapeutic community
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic community (TC) treatment
Trial: 7092633
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol maleate 0.5%, one drop every 12 hours
Trial: 31646623
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nicotine patches)
Trial: 14973800
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat (0.08 mg/kg)
Trial: 14973800
Drug: Intravenous isotonic
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous isotonic saline solution
Trial: 9042869
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition enriched with omega-3 fatty acids
Trial: 8037492
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy with G‐CSF or bone marrow transplantation
Trial: 8037492
Drug: New promising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New promising drugs for chemotherapy such as taxanes
Trial: 17146380
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amitriptyline at bedtime
Trial: 29668720
Drug: Mechanical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical periodontal therapy plus adjunctive antibiotics (amoxicillin 500 mg and metronidazole 400 mg, 3x/day for 7 days)
Trial: 26234336
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg)
Trial: 12644421
Drug: Onset of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onset of neuromuscular block after vecuronium (0.1 mg kg(‐1)) in diabetic patients
Trial: 8436148
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg/d (increased to 40 mg/d if necessary)
Trial: 31916979
Drug: Standard six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard six cycle IV carboplatin‐paclitaxel chemotherapy (CP)
Trial: 29575254
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2) and nedaplatin (80 mg/m2) administered every 28 days for 5 cycles after radical hysterectomy
Trial: 27404673
Drug: tolvaptan treatment
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tolvaptan treatment for 2 days
Trial: 20015605
Drug: Gender-responsive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-responsive treatment (GRT) program using manualized curricula (Helping Women Recover and Beyond Trauma)
Trial: 20015605
Drug: Gender-responsive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-responsive treatment (GRT) program
Trial: 11428976
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg qid for 12 weeks)
Trial: 1837113
Drug: CB006 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB006 (0.4 mg/kg)
Trial: 1837113
Drug: CB006 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB006 (2 mg/kg)
Trial: 6228938
Drug: Dihydroergotoxine mesylate
RxNorm normalized name: Dihydroergotoxine mesylate
DrugBank: Dihydroergotoxine (DB16602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotoxine mesylate (DHT) 1.5 mg t.i.d.
Trial: 29762690
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral treatment in HIV‐1‐positive infants
Trial: 22209388
Drug: MRC-only (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRC-only (8 individual motivational enhancement sessions and 16 treatment readiness group sessions)
Trial: 7698680
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog (10 micrograms, 2 intravenous pulses)
Trial: 7698680
Drug: GnRH injection
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH injection
Trial: 338136
Drug: MAC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAC therapy (Adriamycin + Melphalan + Cyclophosphamide)
Trial: 338136
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (Cyclophosphamide + Methotrexate + 5-Fluorouracil) after induction therapy
Trial: 27771973
Drug: Amisulpride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50 mg)
Trial: 21126861
Drug: Clear carbohydrate
RxNorm normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear carbohydrate drink (CCD) containing 50 g of carbohydrate
Trial: 21126861
Drug: Drink containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink containing 50 g of carbohydrate, 15 g of glutamine, and antioxidants (ONS)
Trial: 15955273
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulins (IVIg)
Trial: 10569649
Drug: TNK-tPA 30
RxNorm normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNK-tPA 30 mg
Trial: 10569649
Drug: TNK-tPA 50
RxNorm normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNK-tPA 50 mg
Trial: 2520619
Drug: ORS with
RxNorm normalized name: SODIUM FLUORIDE 2.43 mg in 1 g ORAL PASTE, DENTIFRICE [Dr Tichenors With Extra Whitening and Tartar Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS with high sodium but low glucose concentration (Na+ 60, glucose 111 mmol/L)
Trial: 2520619
Drug: ORS containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS containing glycine and a glucose polymer (Na+ 50, glucose 50, glycine 50 mmol/L)
Trial: 5572682
Drug: Condensed polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condensed polyphenol inhalation by byssinotic cardroom workers
Trial: 5572682
Drug: Condensed polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condensed polyphenol inhalation by normal control subjects and non-byssinotic cardroom workers
Trial: 23817340
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose (20 mg/kg)
Trial: 23817340
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose (30 mg/kg)
Trial: 21933752
Drug: Raltegravir once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir once daily (two 400 mg tablets taken together every 24 h)
Trial: 21933752
Drug: Raltegravir twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir twice daily (one 400 mg tablet every 12 h)
Trial: 23807156
Drug: Raltegravir twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir twice daily
Trial: 31926000
Drug: ASP8062 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8062 (single ascending doses)
Trial: 23832433
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of curcumin and fluoxetine
Trial: 23832433
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Curcumin, Fluoxetine, Combination)
Trial: 20215935
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (COMB)
Trial: 19152106
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) activated (ON)
Trial: 19152106
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) inactivated (OFF)
Trial: 8036822
Drug: Three vaccine
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three vaccine doses at M0, M1 and M12
Trial: 8036822
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two doses
Trial: 8036822
Drug: Overall vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall vaccination with CHO‐recombinant vaccine
Trial: 27221952
Drug: Bedtime hypertension
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime hypertension treatment strategy
Trial: 27221952
Drug: Bedtime chronotherapy
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime chronotherapy with >/=1 conventional hypertension medications
Trial: 23782955
Drug: PD 0348292
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD 0348292 (0.1 mg qd to 10 mg qd)
Trial: 23782955
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg bid)